Daily IPO Digest
Daily Digest — September 19, 2026
Published
Not financial or investment advice, and not a solicitation to buy or sell any security or to use our service. This is AI-assisted analysis of public SEC filings, provided for informational purposes only.
Figures are drawn from those filings and checked against them; any interpretation, conclusion or forecast is our analytical opinion rather than a statement of fact. We do not intend to defame any person or entity.
It is generated by an automated pipeline with no human review and will likely contain factual errors, interpretive errors, and errors of omission that misrepresent the business or the offering — none of them intentional. Do not rely on it as the sole basis for any investment decision. Always do your own research.
Hit the market today
Electra Therapeutics (ETRA) · Biologics · Nasdaq
ETRA · Priced · $350 million raised · Nasdaq
Electra Therapeutics is a clinical-stage biologics company targeting hemophagocytic lymphohistiocytosis — a rare, rapidly fatal immune syndrome — with ipsoprubart, its lead anti-CD122 antibody. The company priced 23,333,334 shares at $15.00 per share, raising $350 million in gross proceeds, with estimated net proceeds of approximately $319.9 million before the greenshoe. The entire investment case rests on a 12-patient Phase 1b dataset that showed a 100% overall response rate and 100% eight-week overall survival in frontline malignancy-associated HLH — striking results, but drawn from a single subset of a heterogeneous syndrome. The registrational trial is aimed at all secondary HLH, not just the malignancy-associated form that produced those results. Electra carries an accumulated deficit of $221.9 million and projects its cash runway through 2029. The pivotal question — whether the mechanism travels across HLH triggers — is the one the current data cannot answer.
Just filed
NSCALE (NSCL) · GPU Cloud / IaaS · Terms not yet set
NSCL · Initial S-1 · Terms not yet set
Nscale is a GPU-as-infrastructure company — founded in 2024 — that leases and operates large-scale Nvidia GPU clusters to AI developers and has signed what appear to be two of the largest infrastructure contracts in the sector: $43.8 billion with Microsoft and $44.6 billion with Anthropic. Total contract value across active and contracted work reaches $103.4 billion, against 25,000 GPUs currently active out of 461,000 contracted — the gap between those two numbers is the whole bet. Revenue grew 1,252% year-on-year to reach $33 million in fiscal 2025, while the net loss in the first half of 2026 alone reached $1,020.1 million, driven substantially by fair-value adjustments on convertible instruments. The company has raised $3.3 billion in series financing and carries $2.1 billion in convertible loan notes. Revenue is geographically concentrated — 52.0% from Portugal and 45.0% from Norway — and the filing discloses that OpenAI withdrew from a partnership in 2026. Terms not yet set.
TRex Bio (TRXB) · Immunology Biologics · Terms not yet set
TRXB · Initial S-1 · Terms not yet set
TRex Bio is a clinical-stage immunology company developing TRB-061 and TRB-071, biologics targeting the IL-2 receptor pathway for atopic dermatitis and inflammatory bowel disease. Eli Lilly and Johnson & Johnson's JJDC are both collaborators and equity holders — Lilly's post-IPO ownership is capped at 19.9%, a threshold designed to stay just below consolidation territory — and the company's CEO spent 35 years at Lilly before founding TRex. Total equity financing raised is $220 million, and the company holds approximately $90.9 million in cash and marketable securities. The accumulated deficit stands at approximately $123.6 million; the net loss in the first half of the most recently disclosed period was approximately $29.3 million. Lilly's $55 million upfront payment in 2023 funded the early runway; this offering funds Phase 1b and beyond. The lead compound's composition patent extends to 2044. Terms not yet set.
VME Companies · FPSO EPC / Oilfield Services · Terms not yet set
VME Companies · Initial S-1 · up to $30 million estimated raise · Terms not yet set
Founded in 1985, VME Companies is an offshore energy engineering firm — FPSO topsides fabrication, modular EPC, and separation technology — with roughly 2,000 completed projects and 60 FPSO developments supplied across its history. The filing discloses estimated IPO net proceeds of $30 million against near-term capital requirements of $36.1 million — a gap the company's auditors have flagged with a going-concern paragraph. The balance sheet shows a working capital deficit of approximately $43.7 million and a stockholders' equity deficit of approximately $6.7 million. The operational picture is more nuanced: a $127.1 million backlog with a 98% historical realization rate suggests real underlying demand, but two related-party loans totaling $1.8 million are in default, and the Batam fabrication-yard acquisition that management is counting on requires a $3 million deposit from IPO proceeds before it closes.
Retension Pharmaceuticals · Small Molecule / Resistant Hypertension · Terms not yet set
Retension Pharmaceuticals · Initial S-1 · Terms not yet set
Retension Pharmaceuticals is a two-year-old, 12-employee small-molecule biopharma developing RTN-001, a PDE-5 inhibitor aimed at resistant hypertension. The company has completed nine clinical trials enrolling 243 participants in total and initiated a Phase 2b trial in 2025. It holds approximately $13.5 million in cash — enough to fund the Phase 2b readout, with the primary endpoint data and the capital runway appearing to arrive on roughly the same schedule. R&D spend in the first half of the most recently disclosed period was approximately $6.2 million. An underlying composition-of-matter patent expires in 2027, but a crystalline polymorph patent granted in 2025 extends nominal protection to 2044; the commercial significance of that distinction is the IP question worth tracking. Terms not yet set.
SmartKem (SMTK) · Semiconductor / Restructuring · Terms not yet set
SMTK · Initial S-1 · Terms not yet set
SmartKem is a UK-origin organic semiconductor company registering 30,000,000 shares for resale at an indicated price of $2.35 per share, implying a market cap of approximately $125 million. The company reported revenue of approximately $9.1 million in its most recent fiscal year. The filing reflects a company in transition: two consecutive going-concern opinions and a substantial reverse stock split precede this registration, and the S-1 appears connected to a proposed combination with a South African critical minerals business. A "$500 million committed equity facility" referenced in connection with the filing is a structural construct, not a straightforward cash raise — the shares registered at the indicated price do not produce that figure. The actual capital available and the timeline to close the proposed combination are what matter here.
Sources
Regulatory filings
- SEC filings
Some figures are computed from the source material above.